Intra-Tumor Genetic Heterogeneity in Wilms Tumor: Clonal Evolution and Clinical Implications

EBioMedicine

Volumn 9, Issue , 2016, Pages 120-129

  Cresswell, George D ^a   Apps, John R ^b,c   Chagtai, Tasnim ^b   Mifsud, Borbala ^a   Bentley, Christopher C ^a,d   Maschietto, Mariana ^b   Popov, Sergey D ^e   Weeks, Mark E ^b   Olsen, Øystein E ^c   Sebire, Neil J ^b,c   Pritchard Jones, Kathy ^b,c   Luscombe, Nicholas M ^a,d,f   Williams, Richard D ^b   Mifsud, William ^b,c  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY GRADUATE UNIVERSITY   (Japan)

Author keywords

Copy number aberrations; Intra tumor genetic heterogeneity; Molecular biomarkers; Pediatric solid tumors; Tumor evolution; Tumor multisampling; Wilms tumor

Indexed keywords

TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ALLELE; ARTICLE; CARCINOGENESIS; CHILD; CHROMOSOME 11; CHROMOSOME 1Q; CLINICAL ARTICLE; COPY NUMBER VARIATION; DIFFUSION COEFFICIENT; DNA EXTRACTION; FEMALE; GENETIC HETEROGENEITY; GENETIC MARKER; HETEROZYGOSITY; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NEPHROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; UNIPARENTAL DISOMY; YOUNG ADULT; CLONAL EVOLUTION; DIAGNOSTIC IMAGING; DNA MICROARRAY; GENE DOSAGE; GENETICS; GENOME; HETEROZYGOSITY LOSS; INFANT; KIDNEY TUMOR; PATHOLOGY; PHYSIOLOGY;

ALLELES; BIOMARKERS, TUMOR; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; CLONAL EVOLUTION; FEMALE; GENE DOSAGE; GENOME; HUMANS; INFANT; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; WILMS TUMOR;

EID: 84991650679     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.05.029     Document Type: Article

References (35)

1. Charles, A.K., Brown, K.W., Berry, P.J., Microdissecting the genetic events in nephrogenic rests and Wilms’ tumor development. Am. J. Pathol. 153 (1998), 991–1000.
2. de Bruin, E.C., McGranahan, N., Mitter, R., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346 (2014), 251–256.
3. Diskin, S.J., Li, M., Hou, C., et al. Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res., 36, 2008, e126.
4. Gentleman, R.C., Carey, V.J., Bates, D.M., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol., 5, 2004, R80.
5. Gerlinger, M., Rowan, A.J., Horswell, S., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
6. Gerlinger, M., Horswell, S., Larkin, J., et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46 (2014), 225–233.
7. Gnarra, J.R., Tory, K., Weng, Y., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7 (1994), 85–90.
8. Gratias, E.J., Jennings, L.J., Anderson, J.R., Dome, J.S., Grundy, P., Perlman, E.J., Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group. Cancer 119 (2013), 3887–3894.
9. Greaves, M., Maley, C.C., Clonal evolution in cancer. Nature 481 (2012), 306–313.
10. Grundy, P.E., Breslow, N.E., Li, S., et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J. Clin. Oncol. 23 (2005), 7312–7321.
11. Hales, P.W., Olsen, Ø.E., Sebire, N.J., Pritchard-Jones, K., Clark, C.A., A multi-Gaussian model for apparent diffusion coefficient histogram analysis of Wilms’ tumour subtype and response to chemotherapy. NMR Biomed. 28 (2015), 948–957.
12. McDonald, K., Sebire, N.J., Anderson, J., Olsen, Ø.E., Patterns of shift in ADC distributions in abdominal tumours during chemotherapy—feasibility study. Pediatr. Radiol. 41 (2010), 99–106.
13. Mengelbier, L.H., Karlsson, J., Lindgren, D., et al. Intratumoral genome diversity parallels progression and predicts outcome in pediatric cancer. Nat. Commun., 6, 2015, 6125.
14. Moulton, T., Crenshaw, T., Hao, Y., et al. Epigenetic lesions at the H19 locus in Wilms’ tumour patients. Nat. Genet. 7 (1994), 440–447.
15. Natrajan, R., Williams, R.D., Hing, S.N., et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J. Pathol. 210 (2006), 49–58.
16. Nowell, P.C., The clonal evolution of tumor cell populations. Science 194 (1976), 23–28.
17. Okamoto, K., Morison, I.M., Taniguchi, T., Reeve, A.E., Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 5367–5371.
18. Pinto, E.M., Chen, X., Easton, J., et al. Genomic landscape of paediatric adrenocortical tumours. Nat. Commun., 6, 2015, 6302.
19. Popov, S.D., Vujanic, G.M., Sebire, N.J., et al. Bilateral Wilms tumor with TP53-related anaplasia. Pediatr. Dev. Pathol. 16 (2013), 217–223.
20. Pritchard-Jones, K., Bergeron, C., de Camargo, B., et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms’ tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet 386 (2015), 1156–1164.
21. Remke, M., Cavalli, F., Morrissy, A., et al. Integrated genomics elucidates relative spatial homogeneity of embryonal brain tumors. Mol. Cell Pediatr., 2, 2015, A10.
22. Reulen, R.C., Winter, D.L., Frobisher, C., et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 304 (2010), 172–179.
23. Schleiermacher, G., Michon, J., Ribeiro, A., et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br. J. Cancer 105 (2011), 1940–1948.
24. Schwarz, R.F., Trinh, A., Sipos, B., Brenton, J.D., Goldman, N., Markowetz, F., Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput. Biol., 10, 2014, e1003535.
25. Scott, R.H., Douglas, J., Baskcomb, L., et al. Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) robustly detects and distinguishes 11p15 abnormalities associated with overgrowth and growth retardation. J. Med. Genet. 45 (2008), 106–113.
26. Scott, R.H., Douglas, J., Baskcomb, L., et al. Constitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumor. Nat. Genet. 40 (2008), 1329–1334.
27. Segers, H., van den Heuvel-Eibrink, M.M., Williams, R.D., et al. Gain of 1q is a marker of poor prognosis in Wilms’ tumors. Genes Chromosom. Cancer 52 (2013), 1065–1074.
28. van de Wiel, M.A., van Wieringen, W.N., CGHregions: dimension reduction for array CGH data with minimal information loss. Cancer Informat., 2007 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675846/.
29. van de Wiel, M.A., Kim, K.I., Vosse, S.J., van Wieringen, W.N., Wilting, S.M., Ylstra, B., CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics 23 (2007), 892–894.
30. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
31. Vujanić, G.M., Sandstedt, B., Harms, D., Kelsey, A., Leuschner, I., de Kraker, J., Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med. Pediatr. Oncol. 38 (2002), 79–82.
32. Walz, A.L., Ooms, A., Gadd, S., et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27 (2015), 286–297.
33. Wegert, J., Wittmann, S., Leuschner, I., Geissinger, E., Graf, N., Gessler, M., WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosom. Cancer 48 (2009), 1102–1111.
34. Wegert, J., Ishaque, N., Vardapour, R., et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27 (2015), 298–311.
35. Williams, R.D., Chagtai, T., Alcaide-German, M., et al. Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 6 (2015), 7232–7243.